Beneficial effect of soy isoflavones on bone mineral content was modified by years since menopause, body weight, and calcium intake: a double-blind, randomized, controlled trial

Chen, Yuming; Ho, Suzanne C.; Lam, Silvia Siu-Yin; Ho, S.; Woo, Jean

doi:10.1097/01.gme.0000094394.59028.46

Cited by 59 publications

(31 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our literature search identified 31 RCTs. Twenty-two studies were excluded because of lack of indices of interest (Agnusdei et al, 1997a, b;Gambacciani et al, 1997a, b;Potter et al, 1998;Alekel et al, 2000;Wangen et al, 2000;Clifton-Bligh et al, 2001;Katase et al, 2001;Anderson et al, 2002;Chiechi et al, 2002;Lucas et al, 2002;Chen et al, 2003Chen et al, , 2004Jones et al, 2003;Schult et al, 2003;Atkinson et al, 2004;Harkness et al, 2004;Olsen et al, 2004;Mori et al, 2004a, b), non-randomization (Dalais et al, 1998), lack of a control group (Agnusdei et al, 1997a, b), insufficient original data or baseline values (Gambacciani et al, 1997a, b;Khalil et al, 2002). Thus, nine studies with a total of 432 subjects were included in this meta-analysis, in which five studies had quality score of five; three studies had quality score of four and one study had quality score of three (Morabito et al, 2002;Uesugi et al, 2002;Yamori et al, 2002;Arjmandi et al, 2003Arjmandi et al, , 2005Dalais et al, 2003;Brooks et al, 2004;Mori et al, 2004a, b;Nikander et al, 2004) (Table 1).…”

Section: Resultsmentioning

confidence: 99%

Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials

et al. 2007

Eur J Clin Nutr

129

View full text Add to dashboard Cite

Objective: To clarify the effects of isoflavone intake on bone resorption and bone formation. Methods: We identified randomized controlled trials related to urinary deoxypyridinoline (Dpyr, a bone resorption marker) and serum bone-specific alkaline phosphatase (BAP, a bone formation marker) listed on MEDLINE (January 1966-April 2006, the Cochrane Controlled Trials Register, EMBASE (1985( -January 2006, Science Citation Index and PUBMED (updated till April 2006). Results: Nine studies with a total of 432 subjects were selected for meta-analysis. The urinary Dpyr concentration in subjects who consumed isoflavones decreased significantly by À2.08 nmol/mmol (95% confidence interval (CI): À3.82 to À0.34 nmol/ mmol) in comparison with that in subjects who did not consume isoflavones. Isoflavone intake vs placebo intake significantly increased serum BAP by 1.48 mg/l (95% CI: 0.22-2.75 mg/l). Decreases in the urinary Dpyr concentration with isoflavone intake of o90 mg/day and with treatment lasting less than 12 weeks were À2.34 nmol/mmol (95% CI: À4.46 to À0.22 nmol/mmol) and À2.03 nmol/mmol (95% CI: À3.20 to À0.85 nmol/mmol), respectively. Conclusions: Isoflavone intervention significantly inhibits bone resorption and stimulates bone formation. These favorable effects occur even if o90 mg/day of isoflavones are consumed or the intervention lasts less than 12 weeks.

show abstract

Section: Resultsmentioning

confidence: 99%

Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials

et al. 2007

Eur J Clin Nutr

129

View full text Add to dashboard Cite

show abstract

“…18 Table 2 lists studies on humans in response to the effect of SI. Some studies showed significant prevention in bone loss (BMD/BMC) over the duration of the studies 35,46,47,[58][59][60][61][62][63][64][65][66][67][68] ; others did not prove to have significant effects. 18,[69][70][71][72][73][74][75][76][77][78][79] Bone remodeling is a slow process.…”

Section: Intervention Materialsmentioning

confidence: 99%

Soy Isoflavones and Osteoporotic Bone Loss: A Review with an Emphasis on Modulation of Bone Remodeling

Zheng

Lee

Chun

2016

Journal of Medicinal Food

127

View full text Add to dashboard Cite

Osteoporosis is an age-related disorder that affects both women and men, although estrogen deficiency induced by menopause accelerates bone loss in older women. As the demographic shifts to a more aged population, a growing number of men and women will be afflicted with osteoporosis. Since the current drug therapies available have multiple side effects, including increased risk of developing certain types of cancer or complications, a search for potential nonpharmacologic alternative therapies for osteoporosis is of prime interest. Soy isoflavones (SI) have demonstrated potential bone-specific effects in a number of studies. This article provides a systematic review of studies on osteoporotic bone loss in relation to SI intake from diet or supplements to comprehensively explain how SI affect the modulation of bone remodeling. Evidence from epidemiologic studies supports that dietary SI attenuate menopause-induced osteoporotic bone loss by decreasing bone resorption and stimulating bone formation. Other studies have also illustrated that bone site-specific trophic and synergistic effects combined with exercise intervention might contribute to improve the bioavailability of SI or strengthen the bonespecific effects. To date, however, the effects of dietary SI on osteoporotic bone loss remain inconclusive, and study results vary from study to study. The current review will discuss the potential factors that result in the conflicting outcomes of these studies, including dosages, intervention materials, study duration, race, and genetic differences. Further well-designed studies are needed to fully understand the underlying mechanism and evaluate the effects of SI on osteoporosis in humans.

show abstract

“…Previous animal studies have shown that genistein treatment increased bone mineral density (BMD) and improved bone biomechanical performance in ovariectomized (OVX) rodents [12,13] . Clinical studies have also demonstrated that phytoestrogen can effectively increase the BMD of vertebrae and hip bones in postmenopausal women without side effects, which suggested that genistein plays an important role in the regulation of bone formation and bone resorption [14][15][16][17] . phosDose-dependent effects of genistein on bone homeostasis in rats' mandibular subchondral bone www.chinaphar.com Li YQ et al Acta Pharmacologica Sinica npg phatase (ALP) and osteocalcin (OC) are widely used markers for bone formation.…”

Section: Introductionmentioning

confidence: 99%

Dose-dependent effects of genistein on bone homeostasis in rats' mandibular subchondral bone

Xing

Wang

et al. 2011

Acta Pharmacol Sin

View full text Add to dashboard Cite

Aim: To investigate the effect of genistein on bone homeostasis in mandibular subchondral bone of rats. Methods: Female SD rats were administered with genistein (10 and 50 mg/kg) or placebo by oral gavage for 6 weeks. Then the animals were sacrificed, and histomorphology and micro-structure of mandibular condyle were examined using HE staining and micro-CT analysis, respectively. The expression levels of alkaline phosphatase (ALP), osteocalcin (OC), osteoprotegerin (OPG), the receptor activator of nuclear factor κB ligand (RANKL) and estrogen receptors (ERs) in mandibular condyle were detected using real-time PCR. Cultured osteoblasts were prepared from rat mandibular condyle for in in vitro study. The cells were treated with genistein (10 -7 or 10 -4 mol/L) for 48 h. The expression of the bone homeostasis-associated factors and estrogen receptors (ERs) was detected using realtime PCR, and ER silencing was performed. Results: At both the low-and high-doses, genistein significantly increased the bone mineral density (BMD) and bone volume, and resulted in thicker subchondral trabecular bone in vivo. In both in vivo and in vitro study, the low-dose genistein significantly increased the expression of ALP, OC and OPG, but decreased the expression of RANKL and the RANKL/OPG ratio. The high-dose genistein decreased the expression of all these bone homeostasis-associated factors. Both the low and high doses of genistein significantly increased the expression of ERβ, while ERα expression was increased by the low dose genistein and decreased by the high dose genistein. ERβ silencing abrogated most of the effects of genistein treatment. Conclusion: In rat mandibular condylar subchondral bone, low-dose genistein increases bone formation and inhibit bone resorption, while excess genistein inhibits both bone formation and resorption. The effects of genistein were predominantly mediated through ERβ.

show abstract

Beneficial effect of soy isoflavones on bone mineral content was modified by years since menopause, body weight, and calcium intake: a double-blind, randomized, controlled trial

Abstract: The independent effect of soy on the maintenance of hip BMC is more marked in women in later menopause or those with lower BW or calcium intake.

Cited by 59 publications

References 32 publications

Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials

Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials

Soy Isoflavones and Osteoporotic Bone Loss: A Review with an Emphasis on Modulation of Bone Remodeling

Dose-dependent effects of genistein on bone homeostasis in rats' mandibular subchondral bone

Contact Info

Product

Resources

About